Cargando…

Peripheral neuropathy associated with monomethyl auristatin E-based antibody-drug conjugates

Since the successful approval of gemtuzumab ozogamicin, antibody-drug conjugates (ADCs) have emerged as a pivotal category of targeted therapies for cancer. Among these ADCs, the use of monomethyl auristatin E (MMAE) as a payload is prevalent in the development of ADC drugs, which has significantly...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Zhiwen, Gao, Chen, Wu, Tingting, Wang, Lulu, Li, Shijun, Zhang, Yu, Shi, Chen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10505985/ https://www.ncbi.nlm.nih.gov/pubmed/37727735 http://dx.doi.org/10.1016/j.isci.2023.107778

Ejemplares similares

Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E
por: Wang, Yichen, et al.
Publicado: (2018)

Development and Properties of Valine-Alanine based Antibody-Drug Conjugates with Monomethyl Auristatin E as the Potent Payload
por: Wang, Yanming, et al.
Publicado: (2017)

Monomethyl auristatin antibody and peptide drug conjugates for trimodal cancer chemo-radio-immunotherapy
por: Hingorani, Dina V., et al.
Publicado: (2022)

A monomethyl auristatin E-conjugated antibody to guanylyl cyclase C is cytotoxic to target-expressing cells in vitro and in vivo
por: Gallery, Melissa, et al.
Publicado: (2018)

Fibroblast Growth Factor 2 Conjugated with Monomethyl Auristatin E Inhibits Tumor Growth in a Mouse Model
por: Krzyscik, Mateusz A., et al.
Publicado: (2021)

Monomethyl Auristatin E Grafted-Liposomes to Target Prostate Tumor Cell Lines
por: Abawi, Ariana, et al.
Publicado: (2021)

Preclinical Evaluation of 9MW2821, a Site-Specific Monomethyl Auristatin E–based Antibody–Drug Conjugate for Treatment of Nectin-4–expressing Cancers
por: Zhou, Wei, et al.
Publicado: (2023)

Whole-Body Pharmacokinetics and Physiologically Based Pharmacokinetic Model for Monomethyl Auristatin E (MMAE)
por: Chang, Hsuan Ping, et al.
Publicado: (2021)

Tumor-Specific Monomethyl Auristatin E (MMAE) Prodrug Nanoparticles for Safe and Effective Chemotherapy
por: Cho, Hanhee, et al.
Publicado: (2022)

Synthesis and Evaluation of a Monomethyl Auristatin E—Integrin α(v)β(6) Binding Peptide–Drug Conjugate for Tumor Targeted Drug Delivery
por: Davis, Ryan A., et al.
Publicado: (2023)

Purification and In Vitro Evaluation of an Anti-HER2 Affibody-Monomethyl Auristatin E Conjugate in HER2-Positive Cancer Cells
por: Damiani, Isabella, et al.
Publicado: (2021)

Light-Activated Monomethyl Auristatin E Prodrug Nanoparticles for Combinational Photo-Chemotherapy of Pancreatic Cancer
por: Cho, In Kyung, et al.
Publicado: (2022)

Cytotoxic Conjugates of Fibroblast Growth Factor 2 (FGF2) with Monomethyl Auristatin E for Effective Killing of Cells Expressing FGF Receptors
por: Krzyscik, Mateusz Adam, et al.
Publicado: (2017)

Synthesis and Biological Evaluation of RGD and isoDGR–Monomethyl Auristatin Conjugates Targeting Integrin α(V)β(3)
por: Raposo Moreira Dias, André, et al.
Publicado: (2019)

Bombesin-Tethered Reactive Oxygen Species (ROS)-Responsive Nanoparticles for Monomethyl Auristatin F (MMAF) Delivery
por: Kim, Jihoon, et al.
Publicado: (2021)

Lysosomal P-gp-MDR1 Confers Drug Resistance of Brentuximab Vedotin and Its Cytotoxic Payload Monomethyl Auristatin E in Tumor Cells
por: Liu-Kreyche, Peggy, et al.
Publicado: (2019)

FGF2 Dual Warhead Conjugate with Monomethyl Auristatin E and α-Amanitin Displays a Cytotoxic Effect towards Cancer Cells Overproducing FGF Receptor 1
por: Świderska, Karolina Weronika, et al.
Publicado: (2018)

Hydrophilic Auristatin Glycoside Payload Enables Improved Antibody-Drug Conjugate Efficacy and Biocompatibility
por: Satomaa, Tero, et al.
Publicado: (2018)

Physical characteristics comparison between maytansinoid-based and auristatin-based antibody-drug conjugates
por: Fujii, Tomohiro, et al.
Publicado: (2021)

Pharmacokinetic and Metabolism Studies of Monomethyl Auristatin F via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry
por: Park, Min-Ho, et al.
Publicado: (2019)

Halogenation at the Phenylalanine Residue of Monomethyl Auristatin F Leads to a Favorable cis/trans Equilibrium and Retained Cytotoxicity
por: Sokka, Iris K., et al.
Publicado: (2021)

Antibody drug conjugate: the “biological missile” for targeted cancer therapy
por: Fu, Zhiwen, et al.
Publicado: (2022)

Combination of the anti-CD30-auristatin-E antibody-drug conjugate (SGN-35) with chemotherapy improves antitumour activity in Hodgkin lymphoma
por: Oflazoglu, Ezogelin, et al.
Publicado: (2008)

Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody–drug conjugate SGN-75
por: Ryan, M C, et al.
Publicado: (2010)

Dual-Warhead Conjugate Based on Fibroblast Growth Factor 2 Dimer Loaded with α-Amanitin and Monomethyl Auristatin E Exhibits Superior Cytotoxicity towards Cancer Cells Overproducing Fibroblast Growth Factor Receptor 1
por: Nawrocka, Daria, et al.
Publicado: (2023)

Treatment-related adverse events associated with HER2-Targeted antibody-drug conjugates in clinical trials: a systematic review and meta-analysis
por: Fu, Zhiwen, et al.
Publicado: (2022)

A Conjugate Based on Anti-HER2 Diaffibody and Auristatin E Targets HER2-Positive Cancer Cells
por: Serwotka-Suszczak, Anna M., et al.
Publicado: (2017)

Controlled coupling of an ultrapotent auristatin warhead to cetuximab yields a next-generation antibody-drug conjugate for EGFR-targeted therapy of KRAS mutant pancreatic cancer
por: Greene, Michelle K., et al.
Publicado: (2020)

Time‐to‐Event Modeling of Peripheral Neuropathy: Platform Analysis of Eight Valine‐Citrulline‐Monomethylauristatin E Antibody–Drug Conjugates
por: Kågedal, Matts, et al.
Publicado: (2019)

Incidence and risk of fatal adverse events in cancer patients treated with HER2-targeted antibody-drug conjugates: a systematic review and meta-analysis of randomized controlled trials
por: Fu, Zhiwen, et al.
Publicado: (2023)

Increasing the Potential of the Auristatin Cancer-Drug Family by Shifting the Conformational Equilibrium
por: Sokka, Iris K., et al.
Publicado: (2019)

CSPG4 as a target for the specific killing of triple-negative breast cancer cells by a recombinant SNAP-tag-based antibody-auristatin F drug conjugate
por: Mungra, Neelakshi, et al.
Publicado: (2023)

Click Chemistry-Generated Auristatin F–Linker–Benzylguanine for a SNAP-Tag-Based Recombinant Antibody–Drug Conjugate Demonstrating Selective Cytotoxicity toward EGFR-Overexpressing Tumor Cells
por: Huysamen, Allan M., et al.
Publicado: (2023)

Structural Basis of Microtubule Destabilization by Potent Auristatin Anti-Mitotics
por: Waight, Andrew B., et al.
Publicado: (2016)

Targeted Delivery of Auristatin-Modified Toxins to Pancreatic Cancer Using Aptamers
por: Kratschmer, Christina, et al.
Publicado: (2017)

Comparison of a mouse and a novel human scFv-SNAP-auristatin F drug conjugate with potent activity against EGFR-overexpressing human solid tumor cells
por: Woitok, Mira, et al.
Publicado: (2017)

Dimethyl Fumarate and Monomethyl Fumarate Promote Post-Ischemic Recovery in Mice
por: Yao, Yang, et al.
Publicado: (2016)

Ethylene glycol monomethyl ether and propylene glycol monomethyl ether: metabolism, disposition, and subchronic inhalation toxicity studies.
por: Miller, R R, et al.
Publicado: (1984)

Recombinant Antibody-Based and Computer-Aided Comprehensive Analysis of Antibody’s Equivalent Recognition Mechanism of Alternariol and Alternariol Monomethyl Ether
por: Wang, Zile, et al.
Publicado: (2022)

Monomethyl fumarate prevents alloimmune rejection in mouse heart transplantation by inducing tolerogenic dendritic cells: Monomethyl fumarate prevents alloimmune rejection
por: Chen, Juntao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rl3onr729p4rs21ua80oujuj0m